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Abstract 
Background Previous studies relating increased thromboxane (TX) biosynthesis to 
cardiovascular risk factors do not answer the question whether platelet activation is merely 
a consequence of more prevalent atherosclerotic lesions or reflects the influence of 
metabolic and hemodynamic disturbances on platelet biochemistry and function. 
Methods and Results We examined 64 patients with large-vessel peripheral arterial 
disease and 64 age- and sex-matched control subjects. TXA2 biosynthesis was 
investigated in relation to cardiovascular risk factors by repeated measurements of the 
urinary excretion of its major enzymatic metabolite, 11-dehydro-TXB2, by 
radioimmunoassay. Urinary 11-dehydro-TXB2 was significantly (P=.0001) higher in patients 
with peripheral arterial disease (57±26 ng/h) than in control subjects (26±7 ng/h). Seventy 
percent of patients had metabolite excretion >2 SD above the normal mean. However, 11-
dehydro-TXB2 excretion was enhanced only in association with cardiovascular risk factors. 
Multivariate analysis showed that diabetes, hypercholesterolemia, and hypertension were 
independently related to 11-dehydro-TXB2 excretion. During a median follow-up of 48 
months, 8 patients experienced major vascular events. These patients had significantly 
(P=.001) higher 11-dehydro-TXB2 excretion at baseline than patients who remained event 
free. 
Conclusions The occurrence of large-vessel peripheral arterial disease per se is not a 
trigger of platelet activation in vivo. Rather, the rate of TXA2 biosynthesis appears to reflect 
the influence of coexisting disorders such as diabetes mellitus, hypercholesterolemia, and 
hypertension on platelet biochemistry and function. Enhanced TXA2 biosynthesis may 
represent a common link between such diverse risk factors and the thrombotic 
complications of peripheral arterial disease. 
Enhanced platelet biosynthesis of the proaggregative, vasoconstrictive substance 
thromboxane (TX) A2 has been associated with several cardiovascular risk factors. These 
include cigarette smoking,123 non–insulin-dependent diabetes mellitus,4 type IIa 
hypercholesterolemia,5 and homozygous homocystinuria.6 An unresolved question is 
whether persistent platelet activation in these settings is merely a consequence of more 
prevalent atherosclerotic lesions or reflects the influence of the accompanying metabolic 
and hemodynamic disturbances on platelet biochemistry and function.7 
Arteriosclerosis obliterans of the lower limbs is an indicator of diffuse atherosclerotic 
disease and is associated with greatly increased cardiovascular and cerebrovascular 
morbidity and mortality.8910 Moreover, a strong association of conventional risk factors with 
large-vessel peripheral arterial disease has been demonstrated.111213 
In the present study, we sought to determine whether the biosynthesis of TXA2 is altered in 
vivo through repeated measurements of the urinary excretion of its major enzymatic 
metabolites in patients with stable, large-vessel peripheral arterial disease. We compared 
a group of patients without any of the major cardiovascular risk factors (diabetes, 
hypertension, hypercholesterolemia, or smoking) to patients with these risk factors to 
evaluate the relative contribution of atherosclerosis per se versus the presence of these 
risk factors in affecting the rate of TXA2 biosynthesis in vivo. Furthermore, we examined in 
a preliminary fashion the hypothesis that enhanced TXA2 biosynthesis is associated with 
vascular complications during a 4-year follow-up period. 
Methods 
Subjects 
Sixty-four patients with large-vessel peripheral arterial disease (17 women and 47 men 
aged 62.5±8.9 years; range, 37 to 77 years) and 64 age- and sex-matched healthy 
subjects (17 women and 47 men aged 60.4±5.8 years; range, 35 to 75 years) were studied 
at four clinical centers on several occasions between March 1989 and December 1994 
(Table 1). Informed consent was obtained from each participating subject. The study 
protocols were approved by the internal medicine review boards of our institutions. 
Patients with peripheral arterial disease were selected for having at least one of the risk 
factors known to be associated with enhanced TXA2 biosynthesis, ie, cigarette smoking, 
diabetes mellitus, and type IIa hypercholesterolemia, or none of the above. The study 
aimed at recruiting at least 12 patients in each group, and the length of the recruitment 
phase was related to the relatively rare occurrence of patients without any such risk 
factors. Because of the high prevalence of cigarette smoking (39%) and hypertension 
(25%) in the entire study group (Table 1), it was inevitable that such risk factors were 
present in a variable proportion in addition to diabetes mellitus, type IIa 
hypercholesterolemia, or both. Sixty-four healthy subjects were recruited by the same 
participating clinical centers and matched by age and sex to the study patients. Although 
they were selected for not having any cardiovascular risk factors, 2 were later found to be 
cigarette smokers and 1 to be hypertensive. 
Peripheral arterial disease was defined both by a history of intermittent claudication 
localized to the calf with no resting pain and relieved within 10 minutes by rest14 and by an 
ankle-arm index ≤0.85 at rest. 
The ankle-arm index, the ratio of ankle to arm systolic blood pressure, usually ≥1.0 in 
normal adults,1415161718 was measured according to a standard protocol by trained 
technicians.15 
The patients had unilateral (n=12) or bilateral (n=52) disease. In none of the patients had 
arterial disease undergone detectable progression during the previous 6 months as judged 
by clinical evaluation during outpatient visits. Moreover, all had mild-to-moderate 
symptoms. Approximately one third of patients had one or more additional signs of 
atherosclerotic arterial disease, such as stable angina pectoris, previous myocardial 
infarction, or a history of transient cerebral ischemia (Table 1). 
Non–insulin-dependent diabetes mellitus was defined in accordance with the criteria of the 
American Diabetes Association.19 Type IIa hypercholesterolemia was defined in 
accordance with WHO criteria20 on the basis of the determination of total plasma 
cholesterol and triglyceride levels after a 12-hour fast. Hypertension was defined as 
current systolic or diastolic blood pressure >140/90 mm Hg.21 Blood pressure was 
measured both in the supine and standing positions. Smokers were currently smoking 5 to 
30 cigarettes per day. The smoking habit was confirmed by careful history documenting 
regular smoking for ≥1 year. No participant smoked pipes or cigars. All measurements that 
led to categorization into the different subgroups were performed repeatedly (at least 
twice) during a 6-month period. 
All patients were asked to abstain from taking any nonsteroidal anti-inflammatory or 
antiplatelet drug for at least 15 days before the study. Peripheral arterial disease patients 
who also had non–insulin-dependent diabetes mellitus followed an isocaloric diet and at 
the time of study were being treated with oral hypoglycemic drugs or insulin (intermediate-
acting and regular insulin) for several months. Peripheral arterial disease patients with 
hypercholesterolemia followed a hypocholesterolemic diet at the time of study. 
Patients with liver failure or renal disease (creatinine clearance <80 mL/min, serum 
creatinine level >2 mg/dL, urinary albumin excretion >0.3 g/d) as well as patients with 
body-mass index >28 were excluded from the study. 
Design of the Studies 
In the first study, a cross-sectional comparison of 11-dehydro-TXB2 excretion was 
performed between patients and control subjects. Urine was collected from each subject 
during the 12-hour period preceding blood sampling; the samples were frozen immediately 
and kept at −20°C until extraction. The reproducibility of TXA2 biosynthesis was assessed 
by obtaining an additional urine sample a week later from all patients. In 14 patients, a 
third urine sample was obtained after a 2-year follow-up. 
In a second study, we examined whether the metabolic disposition of TXB2 is altered in 
peripheral arterial disease in association with cigarette smoking3 by measuring the urinary 
excretion of its major enzymatic metabolites, ie, 11-dehydro-TXB2 and 2,3-dinor-
TXB2.22 For this study, urine samples were obtained from six smokers with peripheral 
arterial disease (four men, two women; age range, 46 to 62 years) and six healthy 
nonsmokers (four men, two women; age range, 43 to 60 years). 
A third study was designed to examine the relative contribution of platelet cyclooxygenase 
activity to the enhanced excretion of 11-dehydro-TXB2 associated with cardiovascular risk 
factors. Four patients (two with diabetes mellitus and two with hypercholesterolemia; age 
range, 39 to 69 years) were given aspirin (50 mg/d for 7 days), and 12-hour urine samples 
were obtained before and at the end of aspirin administration and on the 3rd, 5th, 7th, and 
10th day after aspirin was withdrawn. 
Follow-up 
The vital status of the study patients was reviewed annually for 4 years to ascertain the 
occurrence of fatal and nonfatal vascular events. One patient died of stomach cancer and 
five patients were lost to follow-up because they refused to undergo the scheduled visits. 
These five patients were excluded from the analysis of TXA2 biosynthesis in relation to 
vascular complications. For this analysis, stroke, myocardial infarction, and cardiac death 
were considered major vascular events. Stroke was defined as rapid onset of a 
neurological deficit that persisted for ≥24 hours unless death supervened and included 
specific localizing findings confirmed by neurological examination or brain scan, with no 
evidence of an underlying nonvascular cause. Determination of fatal stroke was based on 
death certificate data plus data on preterminal hospitalization with a definite diagnosis of 
stroke. Nonfatal myocardial infarction was defined as typical symptoms plus either typical 
ECG changes (including new Q waves) or significant enzyme elevation. Determination of 
fatal myocardial infarction was based on death within 4 weeks after myocardial infarction. 
Cardiac death was defined as death within 24 hours of the onset of severe cardiac 
symptoms, unrelated to other known causes. 
Analyses 
Immunoreactive 11-dehydro-TXB2 and 2,3-dinor-TXB2 were extracted from 20-mL urine 
aliquots and analyzed by previously validated radioimmunoassay techniques.2324 
All blood samples for lipid, lipoprotein, and apolipoprotein analyses were drawn into 
sodium and potassium EDTA (1 mg/mL). Cholesterol and triglycerides were determined 
enzymatically. HDL cholesterol was determined by the phosphotungstic 
acid/MgCl2 precipitation method. LDL cholesterol was calculated by Friedewald’s 
formula.25 These procedures have been described in detail elsewhere.26 
Statistical Analysis 
Statistical analysis was performed by use of χ2 statistics or Fisher’s exact test (if n≤5) for 
independence and by unpaired t test. The linear regression test was used to assess the 
correlation between continuous variables. When necessary, log transformation was used 
to normalize the data or appropriate nonparametric tests were used.27 The aspirin study 
was analyzed with the Kruskal-Wallis method and Mann-Whitney U test adjusted for 
multiple comparisons. Moreover, the association of 11-dehydro-TXB2 excretion with the 
different cardiovascular risk factors was assessed by multiple regression analysis. 
Results 
The rate of TXA2 biosynthesis, as reflected by the excretion of its major enzymatic 
metabolite, 11-dehydro-TXB2, was significantly (P=.0001) higher in patients with peripheral 
arterial disease (57±26 and 60±32 ng/h, as assessed on two different occasions) than in 
age- and sex-matched control subjects (26±7 ng/h). In 45 (70%) of the 64 patients, 
metabolite excretion was >2 SD above the control mean (Fig 1). 
Influence of Risk Factors 
We analyzed 11-dehydro-TXB2 excretion in prospectively selected subgroups of patients 
with peripheral arterial disease based on the presence of cardiovascular risk factors 
previously associated with enhanced TXA2 biosynthesis.123456 As detailed in Table 2, 11-
dehydro-TXB2 excretion was significantly higher in patients with peripheral arterial disease 
in association with cigarette smoking, non–insulin-dependent diabetes mellitus, 
hypercholesterolemia, or both diabetes mellitus and hypercholesterolemia than in control 
subjects adequately matched for age and sex. Despite comparable arterial disease (Table 
3), patients who had none of the above risk factors excreted 11-dehydro-TXB2 at a rate 
indistinguishable from that of control subjects. Moreover, there was no statistically 
significant correlation between metabolite excretion and the ankle-arm index 
(r=.09; P=.4742). 
As shown in Fig 2, only 1 (7%) of the 14 patients with peripheral arterial disease but 
without risk factors had 11-dehydro-TXB2 excretion above the normal range, in contrast to 
67% to 83% of the other subgroups. Hypertensive patients excreted 11-dehydro-TXB2 at a 
nonsignificantly (P=.1267) higher rate than normotensive patients: 75 (median; range 23 to 
123 ng/h) versus 50 ng/h (range, 20 to 111 ng/h). Because of the high prevalence of 
cigarette smoking (30% to 42%) and hypertension (25% to 38%) in the subgroups of 
patients with other risk factors, we performed a multiple regression analysis of 11-dehydro-
TXB2 excretion rates. Such analysis revealed that only diabetes mellitus (regression 
coefficient of 14.0; standard error of 6.1; P<.03), hypercholesterolemia (regression 
coefficient of 22.4; standard error of 6.3; P<.001), and hypertension (regression coefficient 
of 14.1; standard error of 7.1; P<.05) were independently related to 11-dehydro-
TXB2 excretion. 
Reproducibility of TX Biosynthesis 
In 14 nonselected patients, including patients with (n=11) and without (n=3) cardiovascular 
risk factors, urinary 11-dehydro-TXB2 excretion was measured again after a 2-year follow-
up. Metabolite excretion at 2 years averaged 52±21 versus 52±20 and 59±29 ng/h in the 
two samples obtained at baseline. The intrasubject coefficient of variation of 11-dehydro-
TXB2 excretion averaged 23±7% on the basis of three metabolite measurements in each 
patient. The 3 patients without risk factors, who had perfectly normal metabolite excretion 
rates at baseline (28±8 ng/h), continued to have normal values at 2 years (28±2 ng/h) with 
an intrasubject coefficient of variation (22±4%) indistinguishable from that of patients with 
risk factors (23±8%). 
Does Cigarette Smoking Alter TX Metabolism? 
Cigarette smoking has been reported to alter TXB2 metabolism in humans.3 Thus, we 
performed paired measurements of 11-dehydro-TXB2 and 2,3-dinor-TXB2, the major 
enzymatic metabolites of TXB2 originating via the 11-hydroxy-dehydrogenase and β-
oxidation pathways, respectively, in six patients with peripheral arterial disease who were 
current cigarette smokers and in six age- and sex-matched healthy nonsmokers. The 
urinary excretion of 11-dehydro-TXB2 was enhanced in patients versus control subjects 
(59±19 versus 28±6 ng/h; P=.0037) to the same extent as that of 2,3-dinor-TXB2 (39±17 
versus 17±6 ng/h; P=.0262), thus resulting in a comparable ratio between the two 
metabolites of 1.5 versus 1.6 in patients and control subjects, respectively. A highly 
significant linear correlation was found between individual excretion rates of the two 
TXB2 metabolites (Fig 3). 
Effects of Low-Dose Aspirin on TX Biosynthesis 
To characterize the platelet dependence of enhanced TXA2 biosynthesis in patients with 
peripheral arterial disease and cardiovascular risk factors, we assessed the extent of 
suppression and pattern of recovery of 11-dehydro-TXB2 excretion in response to low-dose 
aspirin (50 mg/d for 7 days). We studied four patients with non–insulin-dependent diabetes 
mellitus or hypercholesterolemia. The basal rate of 11-dehydro-TXB2 excretion averaged 
47±9 ng/h and was significantly (P=.0011) reduced by ≈75%, well into the normal range, at 
the end of 1 week of aspirin administration. As shown in Fig 4, the pattern of recovery of 
11-dehydro-TXB2 excretion after aspirin withdrawal was linear over the next 10 days, a 
finding consistent with the slow pattern of recovery of platelet cyclooxygenase activity after 
acetylation by aspirin.28 
TX Biosynthesis in Relation to Vascular Complications 
During a median follow-up of 48 months, eight patients experienced major vascular 
events. There were four acute myocardial infarctions (three nonfatal and one fatal), three 
acute ischemic strokes (one nonfatal and two fatal), and one cardiac death. Patients who 
experienced these events during follow-up had significantly (P=.001) higher 11-dehydro-
TXB2 excretion at baseline than patients who remained event free: 91 (range, 67 to 127 
ng/h) versus 50 ng/h (range, 16 to 124 ng/h). Eight (100%) of eight and 21 (41%) of 51, 
respectively, had metabolite excretion in excess of the median value (56 ng/h). 
Discussion 
We have previously reported456 that the rate of TXA2 biosynthesis is persistently increased 
in patients with metabolic disorders associated with enhanced risk of thrombotic 
complications. These include non–insulin-dependent diabetes mellitus,4 type IIa 
hypercholesterolemia,5 and homozygous homocystinuria.6 Abnormally high 11-dehydro-
TXB2 excretion could be largely suppressed by low-dose aspirin in these studies, thus 
suggesting that it reflected a platelet source of TXA2 biosynthesis. Moreover, 
pharmacological intervention with intensive insulin treatment,4 simvastatin,26 or 
probucol6 allowed us to demonstrate a role for glycemic control, blood cholesterol levels, 
and oxidative mechanisms, respectively, as determinants of platelet activation in these 
clinical settings. However, because these complex metabolic disorders are also 
accompanied by accelerated atherosclerosis and more prevalent vascular lesions, it was 
not possible in these studies to assess the contribution of vascular disease vis-à-vis the 
underlying metabolic disorder in determining a state of persistent platelet activation. 
The present study was designed to investigate the relative importance of diffuse 
atherosclerotic lesions and cardiovascular risk factors in affecting the determinants of 
platelet activation. Therefore, we investigated the rate of TXA2 biosynthesis2930 in a 
relatively large group of patients with peripheral arterial disease, carefully characterized in 
terms of the extent of vascular involvement and presence of cardiovascular risk factors 
previously associated with enhanced TXA2 biosynthesis. 
The main finding of the present study is that large-vessel peripheral arterial disease per se 
is not a trigger of platelet activation in vivo. Rather, the rate of TXA2 biosynthesis appears 
to reflect the influence of diabetes mellitus, hypercholesterolemia, and hypertension on 
platelet biochemistry and function. We used the ankle-arm blood pressure index as a 
measure of the extent of vascular involvement111617 and compared subgroups of patients 
with presumably comparable severity of atherosclerotic disease. 
In a prospective population study in Sweden,31 an ankle-arm index <0.9 was found to be a 
more powerful marker of generalized arteriosclerotic disease than an ultrasonographically 
detected carotid stenosis of ≥30%. All of our patients had an ankle-arm index <0.85, with 
mean values ranging between 0.60 and 0.63 in the five different subgroups examined 
(Table 3). In the subgroup of patients without major cardiovascular risk factors, mean 11-
dehydro-TXB2 excretion was within 1 SD of the control mean value in age- and sex-
matched healthy subjects (Table 2). Moreover, in the entire study population, there was no 
relationship between the ankle-arm index and the rate of 11-dehydro-TXB2 excretion, thus 
suggesting that the presence of diffuse vascular lesions in patients with large-vessel 
peripheral arterial disease does not provide a stronger stimulus to platelet activation than 
that provided by a lesser degree of vascular involvement in healthy control subjects of 
comparable age. Similarly, TXA2 biosynthesis was normal in the patients with stable 
coronary disease studied by Fitzgerald et al.32 
In contrast, the vast majority (ie, 70% to 80%) of patients with coexisting risk factors had 
abnormally high TXA2 biosynthesis that was reproducible over an extended period of 
observation. On the basis of multiple regression analysis, diabetes mellitus, 
hypercholesterolemia, and high blood pressure were independently related to 11-dehydro-
TXB2 excretion. Cigarette smoking, though associated with enhanced TXA2 biosynthesis 
as reported previously in subjects without peripheral vascular disease,123 was not 
independently correlated with metabolite excretion. We examined the possibility of 
underestimating the actual rate of TXA2 biosynthesis in cigarette smokers because of 
reduced conversion of TXB2 to 11-dehydro-TXB2, as described in healthy cigarette 
smokers.3 However, paired measurements of 11-dehydro-TXB2 and of 2,3-dinor-TXB2, a 
major product of β-oxidation,18 revealed a remarkably similar ratio between the two in 
patients and control subjects (Fig 3). These results tend to exclude altered metabolic 
disposition of TXB2 as a result of cigarette smoking, consistent with data of Rangemark et 
al.33 
The independent contribution of high blood pressure in affecting the rate of 
TXA2 biosynthesis is an unexpected finding of the present study in light of the negative 
findings in a previous study of patients with mild essential hypertension.34 In contrast, the 
independent role of diabetes mellitus and hypercholesterolemia as major determinants of 
enhanced TXA2 biosynthesis in the setting of peripheral arterial disease confirms earlier 
findings in patients with non–insulin-dependent diabetes mellitus4 and type IIa 
hypercholesterolemia.5 
Enhanced TXA2 biosynthesis detected in association with diabetes mellitus and 
hypercholesterolemia was largely suppressed by a daily regimen of low-dose aspirin, and 
recovery of 11-dehydro-TXB2 excretion showed a time course that reflected the rate of 
platelet turnover (Fig 4). Although extraplatelet sources might contribute to total body 
synthesis of TXA2, such contribution appears to be small in patients with peripheral arterial 
disease and comparable to that previously established in healthy subjects.35 
Previous studies363738394041424344454647 examined various aspects of platelet function, including 
TXA2 biosynthesis, in patients with peripheral arterial disease. A large proportion of these 
studies reported abnormal platelet function, as measured ex vivo by various 
techniques,404142 or detected high circulating levels of platelet products.4344454647 The 
limitations of these capacity indexes as well as the pitfalls of plasma measurements of 
platelet products have been discussed previously.730 
The noninvasive measurement of 11-dehydro-TXB2 excretion, a widely accepted method 
of assessing platelet function in vivo,730 has been used in very few studies of patients with 
peripheral arterial disease.36373839 However, these studies were both too small and possibly 
confounded by the uncharacterized presence of cardiovascular risk factors to provide a 
reliable assessment of the contribution of the latter vis-à-vis the underlying vascular 
disease in determining the rate of TXA2 biosynthesis. 
The limited follow-up data from the present study suggest that enhanced 
TXA2 biosynthesis and TXA2-mediated amplification of platelet activation in response to 
plaque fissuring may represent a common link between different risk factors (namely, 
diabetes mellitus, hypercholesterolemia, and hypertension) and the occurrence of 
thrombotic complications in patients with peripheral arterial disease. 
Despite an obvious rationale, there is still substantial uncertainty as to the clinical 
indication for antiplatelet therapy in patients with peripheral arterial disease because of 
inadequate trials in this setting.48 The Antiplatelet Trialists’ Collaboration identified more 
than 20 randomized trials of antiplatelet drugs in more than 3000 patients with intermittent 
claudication and described a 20% odds reduction of major vascular events, which failed to 
reach statistical significance.48 Additional trials49 have not resolved such statistical 
uncertainty about the efficacy of antiplatelet drugs in these patients. It is interesting to note 
that aspirin was used in only 5 of 27 antiplatelet trials, at doses ranging between 975 and 
1500 mg/d.48 Thus, it might be argued that the proper antiplatelet regimen, ie, aspirin 75 to 
100 mg/d,50 has not been tested in patients with peripheral arterial disease. Clearly, a trial 
of adequate size is needed to assess the efficacy and safety of low-dose aspirin in this 
setting. The results of the present study may help to identify a group of patients ideally 
suited for such a trial, ie, those with enhanced 11-dehydro-TXB2 excretion. Moreover, this 
approach may help define guidelines for antiplatelet therapy in patients with peripheral 
arterial disease. 
Table 1. Baseline Characteristics of Patients With Peripheral Arterial Disease and Age- and Sex-Matched Control 
Subjects 
Characteristic Patients (n=64) Control Subjects (n=64) 
Age, y 62.4±8.9 60.4±5.8 
Sex (male/female) 47/17 47/17 
Ankle/arm index 0.60 ±0.1 0.96±0.1 
Table 1. Baseline Characteristics of Patients With Peripheral Arterial Disease and Age- and Sex-Matched Control 
Subjects 
Characteristic Patients (n=64) Control Subjects (n=64) 
Regular cigarette smoking, n 25 2 
Hypertension, n 16 1 
Type II diabetes mellitus, n 26 0 
Clinical evidence of stable coronary or cerebrovascular disease, n 21 0 
Plasma cholesterol, mg/dL 216±51 179±25 
Plasma triglycerides, mg/dL 155±96 129±33 
Concomitant medication, n   
None 23 64 
Antiarrhythmics 2 … 
Digitalis 2 … 
Antianginals 10 … 
Antidiabetics 26 … 
Diuretics 5 … 
Antihypertensives 13 … 
Values are mean±SD. 
Table 2. Urinary Excretion Rate (ng/h) of 11-Dehydro-Thromboxane B2 in Subgroups of Peripheral Arterial Disease 
Patients With or Without Major Cardiovascular Risk Factors Compared With Age- and Sex-Matched Healthy Subjects 
Risk Factor Patients Control Subjects 
None (n=14) 32.0±18.0 27.2±7.3 
Cigarette smoking (n=12) 49.7±16.9 27.3±5.7 
Diabetes mellitus (n=16) 67.0±29.0 28.2±7.9 
Hypercholesterolemia (n=12) 72.7±15.5 24.7±8.9 
Hypercholesterolemia and diabetes (n=10) 77.2±28.8 24.5±7.1 
Values are mean±SD. 
Table 3. Ankle-Arm Index in Subgroups of Peripheral Arterial Disease Patients With or Without Major Cardiovascular 
Risk Factors Compared With Age- and Sex-Matched Healthy Subjects 
Risk Factor Patients Control Subjects 
None (n=14) 0.63±0.07 0.95±0.05 
Cigarette smoking (n=12) 0.60±0.07 0.97 ±0.06 
Diabetes mellitus (n=16) 0.61±0.10 0.95±0.06 
Hypercholesterolemia (n=12) 0.62±0.12 0.97±0.08 
Hypercholesterolemia and diabetes (n=10) 0.60±0.12 0.97±0.06 
Values are mean±SD. 
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Figure 1. Urinary excretion rates of 11-dehydro-thromboxane B2 (TXB2) in 64 patients with 
peripheral arterial disease (PAD) and 64 sex- and age-matched healthy subjects. Dots 
represent individual measurements. Individual patient data are also represented in a 
second sample obtained 1 week later. 
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Figure 2. Urinary excretion rates of 11-dehydro- thromboxane B2 (TXB2) in subgroups of 
patients with peripheral arterial disease (PAD). These patients were prospectively selected 
for having at least one of the risk factors known to be associated with enhanced 
TXA2 biosynthesis, ie, cigarette smoking, diabetes mellitus, and type IIa 
hypercholesterolemia, or none of the above. The dotted lines represent 2 SD above and 
below the mean excretion rate in healthy control subjects. 
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Figure 3. Correlation between the urinary excretion rates of 11-dehydro-thromboxane 
B2 (TXB2) and of 2,3-dinor-TXB2 in six patients with peripheral arterial disease who were 
current cigarette smokers (•) and in six age- and sex-matched control subjects (▴) who 
were nonsmokers. Linear regression analysis yielded a statistically significant correlation 
(r=.934; P=.0001) between the two metabolites. 
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Figure 4. Urinary excretion of 11-dehydro-thromboxane B2 (TXB2) in response to 
administration of aspirin in low doses (50 mg/d) for 1 week to four patients with peripheral 
arterial disease with non–insulin-dependent diabetes mellitus or hypercholesterolemia. 
The graph shows the slow recovery of metabolite excretion after aspirin withdrawal. The 
level of 11-dehydro-TXB2 is expressed as a percentage (mean±SD) of the level observed 
before aspirin administration. Each patient served as his or her own control. 
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